Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    164
    ...
ATC Name B/G Ingredients Dosage Form Price
J02AC02 TRACON G Itraconazole - 100mg 100mg Capsule 559,038 L.L
M02AA15 LOCAGEL G Diclofenac sodium (diethylamine) - 10mg/g 10mg/g Gel 223,078 L.L
N02BE01 UBSADOL CHILDREN'S G Paracetamol - 240mg/5ml 240mg/5ml Elixir 284,127 L.L
N05AH02 LANOLEPT G Clozapine - 100mg 100mg Tablet 1,482,258 L.L
R03BA02 CORTAIR G Budesonide - 1mg/2ml 0.5mg/ml Inhalation suspension for nebuliser 1,209,458 L.L
S01BA01 DEXAFREE G Dexamethasone Phosphate - 1mg/ml 1mg/ml Drops solution 563,070 L.L
A04AA01 NAUSETRON G Ondansetron (HCl dihydrate) - 8mg 8mg Tablet, scored 1,023,880 L.L
B01AB12 HIBOR G Bemiparin Sodium - 3,500IU 3,500IU Injectable solution 1,029,383 L.L
B05BB02 DEXTROSE 5% & SODIUM CHLORIDE 0.9% G Sodium chloride - 0.9g/100ml, Dextrose, H2O - 5g/100ml Injectable solution 182,720 L.L
B05ZA CONCENTRATE SOLUTION FOR HEMODIALYSIS TYPE B+ G Hemodialytics, concentrates - Injectable solution L.L
C08CA01 AMLOCARD 10 G Amlodipine (besylate) - 10mg 10mg Tablet 870,298 L.L
C09DB07 CANDAM G Candesartan cilexetil - 16mg, Amlodipine - 10mg Capsule, hard 923,220 L.L
D04AB01 AVOCAINE G Lidocaine - 10% 10% Spray 400,465 L.L
G03AD02 ECINQ G Ulipristal acetate - 30mg 30mg Tablet, film coated 1,302,183 L.L
J01DD15 SEFARIN G Cefdinir - 125mg/5ml 125mg/5ml Suspension 1,695,929 L.L
J02AC03 VORICONAZOLE STRAGEN G Voriconazole - 50mg 50mg Tablet, coated 15,808,184 L.L
L01BC07 AZACITIDINE ARROW G Azacitidine - 25mg/ml 25mg/ml Injectable suspension 10,967,854 L.L
M02AA15 OLFEN G Diclofenac sodium (diethylamine) - 1% 1% Gel 268,769 L.L
N02BE01 ADOL G Paracetamol - 250mg/5ml 250mg/5ml Suspension, alcohol free 192,169 L.L
R03BA02 BUDECORT G Budesonide - 1mg 1mg Respule 1,226,928 L.L
S01BA01 DEXAFREE G Dexamethasone Phosphate - 1mg/ml 1mg/ml Drops solution 563,070 L.L
A04AA01 NOZENTRIX G Ondansetron - 8mg 8mg Tablet, film coated 1,151,865 L.L
A10BD02 GLYSTOR PLUS G Metformin HCl - 500mg, Glibenclamide - 2.5mg Tablet, film-scored 533,697 L.L
B01AB12 HIBOR G Bemiparin Sodium - 5,000IU 5,000IU Injectable solution 1,466,132 L.L
B05BB02 DEXTROSE 5% & SODIUM CHLORIDE 0.9% G Sodium chloride - 0.9g/100ml, Dextrose, H2O - 5g/100ml Injectable solution 207,894 L.L
B05ZA CONCENTRATE SOLUTION FOR HEMODIALYSIS TYPE J G Hemodialytics, concentrates - Injectable solution L.L
C08CA01 AMLODAR 10 G Amlodipine (besylate) - 10mg 10mg Capsule 671,921 L.L
C09DB07 CORONOPINE G Candesartan cilexetil - 16mg, Amlodipine - 10mg Capsule, hard 1,540,044 L.L
D04AB01 LIDONOSTRUM BOMBA-SPRAY G Lidocaine - 10% 100mg/ml Spray, solution 747,176 L.L
J01DD15 SEFARIN G Cefdinir - 125mg/5ml 125mg/5ml Suspension 939,346 L.L
    ...
    164
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025